UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 16, 2023
(Exact name of registrant as specified in its charter)
|
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (866 ) 688-7374
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on
which registered
|
||
|
|
|
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On June 16, 2023, Quantum-Si Incorporated (the “Company”) and Michael P. McKenna, Ph.D., the Company’s Executive Vice President, Product
Development and Operations, mutually determined that Dr. McKenna will step down from such role, effective as of July 31, 2023. The Company expects to enter into a separation agreement with Dr. McKenna, the terms of which will be consistent with
the Company’s Executive Severance Plan, as amended, and will be disclosed once available.
A copy of the press release announcing Dr. McKenna’s departure is attached hereto as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01 |
Financial Statements and Exhibits.
|
| (d) |
Exhibits.
|
|
Exhibit
No.
|
Description
|
|
|
Press Release dated June 21, 2023.
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
QUANTUM-SI INCORPORATED
|
||
|
By:
|
/s/ Christian LaPointe, Ph.D.
|
|
|
Name:
|
Christian LaPointe, Ph.D.
|
|
|
Title:
|
General Counsel
|
|
|
Date: June 21, 2023
|
||
Exhibit 99.1
Quantum-Si Announces the Appointment of Industry Veteran Johan Denecke as
Senior Vice President of Operations
BRANFORD, Conn., June 21, 2023 — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,”
“QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of Johan Denecke as Senior Vice President of Operations, effective June 20, 2023. Mr. Denecke will be responsible for scaling up production and driving
operational and quality excellence in support of the commercialization of Quantum-Si’s next-generation, single-molecule protein sequencing platform.
Mr. Denecke brings more than 20 years of experience as a cross-functional operations executive in engineering, quality assurance and best-in-class
manufacturing practices. Having held executive positions in both private and public sectors, including at Illumina as Vice President of Manufacturing Engineering, and Thermo Fisher Scientific as Vice President of Quality Assurance, he brings a
wealth of experience to the table. Most recently, he served as Senior Vice President of Operations at Atomica where he scaled the organization yielding significant growth, efficiency, and waste reduction.
“Mr. Denecke has a proven track record of leading high-growth, cross-functional teams that have delivered products with quality, speed and cost
efficiency,” said Dr. Patrick Schneider, President and Chief Operating Officer of Quantum-Si. “His expertise across multiple aspects of global operations and integrated supply chain strategically positions Quantum-Si for growth as it continues its
mission to solve complex biological problems through accessible protein sequencing.”
“With a passion for driving operations excellence, I am honored to serve as a senior member of Quantum-Si’s executive team as we work to optimize our
supply chain and increase operational efficiency to drive higher gross margins. I look forward to leveraging my expertise to help the company achieve its strategic goals and deliver innovative solutions to our customers,” said Mr. Denecke.
Mr. Denecke holds a Bachelor of Science and Master of Science in aerospace engineering from the Massachusetts Institute of Technology.
Michael McKenna, Ph.D., whose service and leadership were integral to the Company’s product development and pre-revenue stage, will transition out of
his role as Executive Vice President of Product Development and Operations at Quantum-Si at the end of July 2023.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing CompanyTM, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act
of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate,"
"project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to
identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These
forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are
difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market;
the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s
ongoing leadership transition; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the
commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized PlatinumTM protein sequencing
instrument and the Company’s other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the
development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the
Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional
financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company’s Annual Report for the fiscal year ended December 31, 2022, and in the Company's other filings with the SEC. The
Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any
obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
Investor Contact
Juan Avendano
ir@quantum-si.com
Media Contact
Michael Sullivan
msullivan@spectrumscience.com